New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 7, 2007, Pages 2036-2042

  Mastalerz, Harold ^a   Chang, Ming ^b   Chen, Ping ^b   Dextraze, Pierre ^c   Fink, Brian E ^b   Gavai, Ashvinikumar ^b   Goyal, Bindu ^b   Han, Wen Ching ^b   Johnson, Walter ^a   Langley, David ^a   Lee, Francis Y ^b   Marathe, Punit ^b   Mathur, Arvind ^b   Oppenheimer, Simone ^b   Ruediger, Edward ^c   Tarrant, James ^a   Tokarski, John S ^b   Vite, Gregory D ^b   Vyas, Dolatrai M ^a   Wong, Henry ^a   Wong, Tai W ^b   Zhang, Hongjian ^b   Zhang, Guifen ^a   more..

^a Pharmaceutical Candidate Optimization   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NONE   (Canada)

Author keywords

EGFR; HER2; Pyrrolotriazine; Receptor tyrosine kinase inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; RIBOSE PHOSPHATE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COLON CARCINOMA; DRUG EFFICACY; ENZYME INHIBITION; MOUSE; NONHUMAN; SUBSTITUTION REACTION; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM TRANSPLANTATION; PHOSPHATES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RIBOSE; TRIAZINES;

EID: 33847792225     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.002     Document Type: Article

References (25)

1. Baselga J., and Arteaga C.L. J. Clin. Oncol. 23 (2005) 2445
2. Kamath S., and Buolamwini J.K. Med. Res. Rev. 26 (2006) 569 and references therein
3. Baselga J. Ann. Oncol. 13 (2002) 8
4. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Kieth B.R., Murray K.G., Knight W.B., Mullin R.J., and Gilmer T.M. Mol. Cancer Ther. 1 (2001) 85
5. Burris H.A. The Oncologist 9 Suppl. 3 (2004) 10
6. Traxler P., Allegrini P.R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grosios K., Lane H.A., McSheehy P.L., Mestan J., Meyer T., Tang C., Wartmann M., Wood J., and Caravatti G. Cancer Res. 64 (2004) 4931
7. Wong T.W., Lee F.Y., Yu C., Luo F.R., Oppenheimer S., Zhang H., Smykla R.A., Mastalerz H., Fink B.E., Hunt J.T., Gavai A.V., and Vite G.D. Clin. Cancer Res. 12 (2006) 6186
8. Hunt J.T., Mitt T., Borzilleri R., Gullo-Brown J., Fargnoli J., Fink B., Han W.-C., Mortillo S., Vite G., Wautlet B., Wong T., Yu C., Zheng X., and Bhide R. J. Med. Chem. 47 (2004) 4054
9. For experimental procedures, see: Mastalerz, H.; Zhang, G.; Tarrant, J.; Vite, G. D. US 6,908,916.
10. Brenner E., Baldwin R.M., and Tamagnan G. Org. Lett. 7 (2005) 937
11. Fernandez P.A., Bellamy T., King M., Madge D.J., and Selwood D.L. Heterocycles 55 (2001) 1813
12. Tsunoda T., Yamamiya Y., and Ito S. Tetrahedron Lett. 34 (1993) 1639
13. Mastalerz H., Gavai A.V., Fink B., Struzynski C., Tarrant J., Vite G.D., Wong T.W., Zhang G., and Vyas D.M. Can. J. Chem. 84 (2006) 528
14. Fink B.E., Vite G.D., Mastalerz H., Kadow J.F., Kim S.-H., Leavitt K.J., Du K., Crews D., Mitt T., Wong T.W., Hunt J.T., Vyas D.M., and Tokarski J.S. Bioorg. Med. Chem. Lett. 15 (2005) 4774
15. Additional cell proliferation data (not shown) using the HER2 overexpressing BT-474 human breast tumor cell line and a constitutively activated Sal2 murine salivary gland tumor that expresses a CD8HER2 fusion protein wer found to track with these observed for the N87 cell line.
16. Smith A.S., and van de Waterbeemd H. Pharmacokinetics and Metabolism in Drug Design (2001), Wiley-VCH, Weinheim 84
17. Smith D.A., Jones C.J., and Walker D.K. Med. Res. Rev. 16 (1996) 243
18. 2O) of 8.3 for morpholine versus 10.2 for 1-amino-3-hydroxypropane from: Perrin, D.D. Dissociation Constants of Organic Bases in Aqueous Solution. Supplement 1972; Butterworths: London, UK, 1972.
19. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., and Shewchuk L. Cancer Res. 64 (2004) 6652
20. Schrodinger, L.L.C. 2003. 32nd Floor, Tower 45, 120 West Forty-Fifth Street, New York, 10036.
21. Kaminski G.A., Friesner R.A., Tirado-Rives J., and Jorgensen W.L. J. Phys. Chem. B 105 (2001) 6474
22. Yu Z., Jacobson M.P., and Friesner R.A. J. Comput. Chem. 27 (2006) 72
23. Ballard P., Bradbury R.H., Harris C.S., Hennequin L.F.A., Hickinson M., Johnson P.D., Kettle J.G., Kinowska T., Leach A.G., Morgentin R., Pass M., Ogilvie D.J., Olivier A., Warin N., and Williams E.J. Bioorg. Med. Chem. Lett. 16 (2006) 1633
24. Ballard P., Bradbury C.S., Hennequin L.F.A., Hickinson M., Johnson P.D., Kettle J.G., Kinowska T., Morgentin R., Ogilvie D.J., and Olivier A. Bioorg. Med. Chem. Lett. 15 (2005) 4226
25. For experimental details, see Ref. 5.